Inclusion Criteria:

          -  1. Previously untreated patients with histologically- or cytologically- documented
             NSCLC who present stage IIIA disease (according to 8th version of the International
             Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). PET/CT
             including IV contrast (CT of diagnostic quality) will be performed at baseline (28
             days +10 before randomization).

          -  2. Tumor should be considered resectable before study entry by a multidisciplinary
             team

          -  3. Sensitizing EGFR mutation (Del Exon 19 and ins Exon 21).

          -  4. ECOG (Performance status) 0-1

          -  5. Screening laboratory values must meet the following criteria and should be obtained
             within 14 days prior to randomization i. Neutrophils ≥ 1500×109/L ii. Platelets ≥ 100
             ×109/L iii. Hemoglobin > 9.0 g/dL iv. Serum creatinine ≤ 1.5 x ULN or creatinine
             clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below): a. Female
             CrCl = (140 - age in years) x weight in kg x 0.85/ 72 x serum creatinine in mg/dL b.
             Male CrCl = (140 - age in years) x weight in kg x 1.00/ 72 x serum creatinine in mg/dL
             v. AST/ALT ≤ 3 x ULN vi. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert
             Syndrome, who can have total bilirubin < 3.0 mg/dL) vii. PT/APTT/INR within normal
             limits

          -  6. Measurable or evaluable disease according to RECIST v1.1.

          -  7. The patients need to have a forced expiratory volume (FEV1)≥ 1.2 liters or >40% p-
             predicted value.

          -  8. All patients are notified of the investigational nature of this study and signed a
             written informed consent in accordance with institutional and national guidelines,
             including the Declaration of Helsinki prior to any trial-related intervention.

          -  9. Patients aged > 18 years.

          -  10. Patient capable of proper therapeutic compliance and accessible for correct
             follow-up.

          -  11. For female patients of childbearing potential, agreement (by patient and/or
             partner) to use a highly effective form(s) of contraception that results in a low
             failure rate (< 1% per year) when used consistently and correctly, and to continue its
             use for 5 months after the last dose of Atezolizumab and/or 6 months after the last
             dose of Bevacizumab, whichever is later. Such methods include: combined (estrogen and
             progestogen containing) hormonal contraception, progestogen-only hormonal
             contraception associated with inhibition of ovulation together with another additional
             barrier method always containing a spermicide, intrauterine device (IUD): intrauterine
             hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on
             the understanding that this is the only one partner during the whole study duration),
             and sexual abstinence.

          -  12. For male patients with female partners of childbearing potential, agreement (by
             patient and/or partner) to use a highly effective form(s) of contraception that
             results in a low failure rate [< 1% per year] when used consistently and correctly,
             and to continue its use for 6 months after the last dose of Bevacizumab. Male patients
             should not donate sperm during this study and for at least 6 months after the last
             dose of Bevacizumab.

          -  13. Oral contraception should always be combined with an additional contraceptive
             method because of a potential interaction with the study drugs. The same rules are
             valid for male patients involved in this clinical study if they have a partner of
             childbirth potential. Male patients must always use a condom.

          -  14. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea)
             or surgically sterile must have a negative serum pregnancy test result within 14 days
             prior to initiation of study drug

        Exclusion Criteria:

          -  1. All patients carrying other EGFR mutations.

          -  2. Patients with known anaplastic lymphoma kinase (ALK) fusion oncogene, STK11 ligand
             alteration or ROS1 translocations.

          -  3. Clinically significant comorbidities that impaired administration of platinum-based
             chemotherapy.

          -  4. Patients with a condition requiring systemic treatment with either corticosteroids
             (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of randomization. Inhaled or topical steroids, and adrenal replacement steroid
             doses > 10 mg daily prednisone equivalent, are permitted in the absence of active
             autoimmune disease.

          -  5. Patients with a history of interstitial lung disease cannot be included if they
             have symptomatic ILD (Grade 3-4) and/or poor lung function. In case of doubt please
             contact trial team.

          -  6. Patients with other active malignancy requiring concurrent intervention and/or
             concurrent treatment with other investigational drugs or anti-cancer therapy.

          -  7. Patients with previous malignancies (except non-melanoma skin cancers, and the
             following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia,
             melanoma, or breast) are excluded unless a complete remission was achieved at least 2
             years prior to study entry AND no additional therapy is required during the study
             period.

          -  8. Any medical, mental or psychological condition which in the opinion of the
             investigator would not permit the patient to complete the study or understand the
             patient information.

          -  9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or
             hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic
             infection.

          -  10. Patients with known history of testing positive for human immunodeficiency virus
             (HIV) or known acquired immunodeficiency syndrome (AIDS).

          -  11. Active tuberculosis.

          -  12. Severe infections within 4 weeks prior to be included in the study, including but
             not limited to hospitalization for complications of infection, bacteremia, or severe
             pneumonia.

          -  13. Patients with history of allergy to study drug components excipients.

          -  14. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins.

          -  15. Women who are pregnant or in the period of breastfeeding.

          -  16. Sexually active men and women of childbearing potential who are not willing to use
             an effective contraceptive method during the study.

          -  17.

               -  Patients with active, known or suspected autoimmune disease, including but not
                  limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus
                  erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular
                  thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis,
                  Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or
                  glomerulonephritis.

               -  Patients with a history of autoimmune-related hypothyroidism on a stable dose of
                  thyroid replacement hormone are eligible for this study.

               -  Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin
                  regimen are eligible for this study.

               -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis would
                  be excluded) are permitted provided that they meet the following conditions:

                    -  Rash must cover less than 10% of body surface area (BSA).

                    -  Disease is well controlled at baseline and only requiring low-potency
                       topical steroids.

                    -  No acute exacerbations of underlying condition within the previous 12 months
                       (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate,
                       retinoids, biologic agents, oral calcineurin inhibitors, high-potency or
                       oral steroids).

          -  18. Patients with any contraindication for bevacizumab administration.